A new strategy, targeting a rare type of immune cells
called bnAbs, to build a vaccine against HIV shows promise by
showing a favourable safety profile in almost all of the
vaccinated persons in a Phase 1 trial.
Contact: info@neat-news.com.
neat-news.com is not responsible for the content of external sites.
We do not link to external sites in return for money or any other benefits.
The page is maintained in Germany and for any legal matters the laws of Germany apply.
Any warranty or liability is excluded in the widest legally possible sense.